Innovation Pharmaceuticals Inc. (IPIX)

USD 0.0

(0.0%)

Market Cap (In USD)

154.2 Thousand

Revenue (In USD)

-

Net Income (In USD)

-3.16 Million

Avg. Volume

168.98 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-4-0.0195
PE
-
EPS
-
Beta Value
0.227
ISIN
US45782D1000
CUSIP
45782D100
CIK
1355250
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Leo Ehrlich CPA
Employee Count
-
Website
https://www.ipharminc.com
Ipo Date
2007-05-04
Details
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer. It has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.